Informing Canada’s Cancer Drug Funding Decisions with Scientific Evidence and Patient Perspectives: The Pan-Canadian Oncology Drug Review

J.S. Hoch; M. Sabharwal

doi:10.3747/co.20.1315

You are currently viewing a new version of our website. To view the old version click .

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Editorial

1 April 2013

Informing Canada’s Cancer Drug Funding Decisions with Scientific Evidence and Patient Perspectives: The Pan-Canadian Oncology Drug Review

and

Pharmacoeconomics Research Unit, Cancer Care Ontario, and Canadian Centre for Applied Research in Cancer Control, Toronto, ON, Canada

Pan-Canadian Oncology Drug Review, Toronto, ON, Canada

Author to whom correspondence should be addressed.

Curr. Oncol.2013, 20(2), 121-124;https://doi.org/10.3747/co.20.1315

Version Notes

Order Reprints

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

JSH: In July 2011, the pan-Canadian Oncology Drug Review [pcodr (http://www.pcodr.ca/)] began accepting submissions by pharmaceutical manufacturers and clinician-based tumour groups to have cancer drugs reimbursed by provincial payers in Canada. Doesn’t Canada already have a body reviewing drugs? [...]

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

New Chart Review Data Validate Administrative Data–Based Indicator for Guideline-Recommended Treatment of Locally Advanced Non-Small-Cell Lung Cancer and Shed Light on Reasons for Non-Referral and Non-Treatment

Cancer Narratives: Words beyond Disease—A Call for Submissions